Conditions: Atopic Dermatitis
Keywords: Eczema
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 422
Healthy volunteers: no

Brief summary:
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.

Detailed description:

Arms:
arm 1: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36. arm 2: Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36. arm 3: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36. arm 4: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.

Interventions: intervention 1: Dupilumab intervention 2: Placebo
Intervention descriptions: intervention 1: Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered. intervention 2: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).

Protocol document: